Text or call a human:Text (808) 600-9260Call
CorporateVentureCapital.com

M Ventures

Profile, fund size and portfolio

Parent Merck KGaA, Darmstadt, GermanyHQ Amsterdam, NetherlandsFounded 2009

M Ventures is the corporate venture arm of Merck KGaA, Darmstadt, Germany, a pharmaceutical and biotech company. It was founded in 2009 and is based in Amsterdam, Netherlands. It invests from Series A to Series C+. Sectors it names: healthcare and digital health, biotech and life sciences, semiconductors and hardware, industrial technology and robotics.

Fund sizeS1
EUR 600M
Companies backedS1
100+
IPOsS3
7

Every figure links to its source

Snapshot

Investment stage: Series A to Series C+
Data behind this graphic
Data behind this graphic
ItemValue
Stage rangeSeries A to Series C+
SectorsHealthcare and digital health, Biotech and life sciences, Semiconductors and hardware, Industrial technology and robotics
GeographyNorth America, Europe, Middle East and Africa
OfficesAmsterdam, Netherlands, Darmstadt, Germany

Sources: S4 M Ventures news archive (2015 to 2026); S3 M Ventures portfolio (category and exit filters); S5 M Ventures contact (offices).

Graphic 1 of 3

Investment stage: Series A to Series C+

Sources: S4 M Ventures news archive (2015 to 2026); S3 M Ventures portfolio (category and exit filters); S5 M Ventures contact (offices).

Download:Report a correction
Investments closed by company type
Data behind this graphic
Data behind this graphic
ItemCompaniesShare
Healthcare4248.8%
Electronics2124.4%
Frontier Technology and Sustainability1214%
Life Science1112.8%

A company can carry more than one tag

Sources: S3 M Ventures portfolio (category and exit filters).

Graphic 2 of 3

Investments closed by company type

Sources: S3 M Ventures portfolio (category and exit filters).

Download:Report a correction
Scale and capital allocated
Data behind this graphic
Data behind this graphic
MeasureValueUnitKindSource
Headline sizeEUR 600MFund sizeStated by the firm or its parentS1
Companies backed100+companiesStated by the firmS1
IPOs7IPOsStated by the firmS3
Companies on the firm's portfolio page86companiesCounted from the firm's own listS3

Sources: S1 M Ventures home; S3 M Ventures portfolio (category and exit filters).

Graphic 3 of 3

Scale and capital allocated

Firms and databases count companies, rounds and investments differently.

Sources: S1 M Ventures home; S3 M Ventures portfolio (category and exit filters).

Download:Report a correction

Where it invests and who leads it

Geography

Headquarters
Amsterdam, Netherlands
Offices

Investment regionsS4S3S5

LeadersS7S6S8S9S10

M Ventures on LinkedIn

Key facts

FactValueStatusSource
Parent companyMerck KGaA, Darmstadt, GermanySingle sourceS1
Parent industryPharmaceuticals and biotechSingle sourceS1
Founded2009Single sourceS1
HeadquartersAmsterdam, NetherlandsSingle sourceS5
StatusActiveSingle sourceS1
Capital sourceParent company onlySingle sourceS1
Headline sizeEUR 600M (Fund size)Single sourceS1
Companies backed100+Single sourceS1
Exits19 total, 7 IPOsSingle sourceS3
People on the team page23Single sourceS2
StagesSeries A, Series B, Series C+ (inferred from announced rounds)EstimateS4

Portfolio

The firm's portfolio page lists 86 companies: 67 active, 19 exited.S3

The firm also states 100+ companies backed. The page list and the stated total measure different things.S1

Companies by status on the firm's list. Status as the firm tags itS3
TagCompaniesShare
Active6777.9%
Exited1922.1%
Portfolio by the firm's own tags. A company can carry more than one tagS3
TagCompaniesShare
Healthcare4248.8%
Electronics2124.4%
Frontier Technology and Sustainability1214%
Life Science1112.8%

Shared portfolio with other corporate VCs

39 companies on the M Ventures portfolio page also appear on the portfolio page of at least one other firm in this directory. Matched by company website, or by name where no website is published.

FirmSharedCompanies in common
Pfizer Ventures5FoRx Therapeutics, Storm Therapeutics, TRIMTECH Therapeutics, Enara Bio, TwoStep Therapeutics
Applied Ventures3Metalenz, Electroninks, Lumiode
Intel Capital3Metalenz, ChEmpower, UNISERS
Taiho Ventures3Storm Therapeutics, Anavo, Theolytics
MP Healthcare Venture Management3TRIMTECH Therapeutics, Outrun Therapeutics, ribometrix
TEL Venture Capital2FMC, ChEmpower
Koch Disruptive Technologies2Celestial AI, Polaris Electro-Optics
Qualcomm Ventures2Medisafe, Wiliot
Sanofi Ventures2Medisafe, Nucleai
TDK Ventures2Metalenz, NovoLINC
Novartis Venture Fund2FoRx Therapeutics, NRG Therapeutics
Debiopharm Innovation Fund2Nucleai, Iktos

Companies backed by the most corporate VCs

Every company on the M Ventures list

86 companies, as listed on the firm's own website: 67 active, 19 exited.S3 Read the firm's list.

Active 67

  • Abselion
  • Actithera
  • Altoida
  • Anavo
  • Anjuna Security
  • Artios
  • Asceneuron
  • Astraveus
  • beeOLED
  • Biolinq
  • CellFE
  • ChEmpower
  • Concerto Biosciences
  • Corvic AI
  • Cyllene Therapeutics
  • DISCO Pharmaceuticals
  • DNA SCRIPT
  • Electroninks
  • Enara Bio
  • Ferroelectric Memory
  • Formo
  • FoRx Therapeutics
  • Future Fertility
  • Genopore
  • IKAS
  • Iktos
  • ImmuneBridge
  • iOmx Therapeutics
  • iOnctura
  • IonKraft
  • Kivu Bioscience
  • LabGenius
  • Lightcast
  • Lucidean
  • Medisafe
  • MemryX
  • Metalenz
  • Mosa Meat
  • Multitude
  • NanoSyrinx
  • NeoLogic
  • Neurable
  • Nouscom
  • NovoLINC
  • NRG Therapeutics
  • Nucleai
  • Nucleome
  • Outrun Therapeutics
  • Pacific Light & Hologram
  • PictorLabs
  • Plexium
  • Polaris Electro-Optics
  • PxE
  • Quintessent
  • Remepy
  • ReproNovo
  • Rewind
  • ribometrix
  • SEEQC
  • Storm Therapeutics
  • SynSense
  • Theolytics
  • Thintronics
  • TRIMTECH Therapeutics
  • TwoStep Therapeutics
  • UNISERS
  • Wiliot

Exited 19

  • Akili
  • Ambrx
  • Calypso Biotech
  • Celestial AI
  • EpiTherapeutics
  • F-Star Therapeutics
  • Forendo Pharma
  • Galecto Biotech
  • Immunitas
  • Immunorizon
  • Lumiode
  • ObsEva
  • Padlock Therapeutics
  • Prexton Therapeutics
  • Progyny
  • Synaffix
  • TIGNIS
  • Translate Bio
  • x.ilio Therapeutics

Fund vehicles

VehicleSizeYearSource
M Ventures allocation (new investment by Merck KGaA)EUR 600M2021S13
Healthcare-only allocation at earlier stageEUR 150MS6

Recent rounds

DateCompanyRoundAmountLed by the firmSource
2026-09-16Polaris Electro-OpticsSeries BUSD 50MNoS4
2026-09-10TwoStep TherapeuticsSeries AUSD 62.5MNoS4
2026-07-07Cyllene TherapeuticsSeries C+EUR 33MYesS4
2025-07-09ActitheraSeries AUSD 75.5MNoS14

History

  1. Inception of M Ventures.S1
  2. Hakan Goker joins M Ventures.S7
  3. Electronics, Frontier Tech and Sustainability and Life Science funds incepted.S6
  4. Merck KGaA expands M Ventures with a new EUR 600 million investment (8 Dec 2021).S13
  5. Javier Rodriguez becomes head of the Technology team.S6

Official pages

Read the firm's own pages for current information.

Sources

  1. S1M Ventures homeFirm
  2. S2M Ventures teamFirm
  3. S3M Ventures portfolio (category and exit filters)Firm
  4. S4M Ventures news archive (2015 to 2026)Firm
  5. S5M Ventures contact (offices)Firm
  6. S6M Ventures: Javier Rodriguez bioFirm
  7. S7M Ventures: Hakan Goker bioFirm
  8. S8M Ventures: Bauke Anninga bioFirm
  9. S9M Ventures: Christian Patze bioFirm
  10. S10M Ventures: Christian Uhrich bioFirm
  11. S13M Ventures: Merck KGaA expands M Ventures with a new EUR 600 million investment (Dec 2021)Firm
  12. S14M Ventures: Actithera raises USD 75.5M Series AFirm

Disclaimer and corrections

Not affiliated. This page is not affiliated with, endorsed by or sponsored by M Ventures or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.

Spotted a mistake? Report a correction.